drugset
Drugs / CAR19
last change Feb 2026 re-read 9 days ago

CAR19

also known as CAR19 T cells

Cell therapy targets CD19

Developed for
acute myeloid leukemia · aggressive B-cell non-Hodgkin lymphoma · B-cell acute lymphoblastic leukemia · childhood acute lymphoblastic leukemia · plasma cell myeloma · T lymphoblastic leukemia/lymphoma · T-cell non-Hodgkin lymphoma
Investigated by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Hebei Taihe Chunyu Biotechnology Co., Ltd · Tianjin Medical University General Hospital

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2025-12-08 Orca Biosystems, Inc. Results Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 67th American Society of Hematology Annual Meeting orcabio.com ↗
2025-11-03 Orca Biosystems, Inc. Results Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 67th American Society of Hematology Annual Meeting orcabio.com ↗
Superior Efficacy and Persistence of Orca-T-Allogeneic CAR19/22 Versus Autologous CAR19/22 in High-Risk Adult B-ALL
2024-10-17 Nektar Therapeutics Results Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia nektar.com ↗
The data published in Blood showed favorable efficacy with eight out of nine patients (89%) whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease (MRD) negative remission.
2021-12-13 Celularity Incorporated Results Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition celularity.com ↗
The results demonstrate the feasibility and functionality of expressing a Chimeric Antigen Receptor (CAR) directed to CD19 on placental CD34 + derived, cryopreserved, off-the-shelf, allogeneic CYNK cells.
2021-12-10 Caring Cross Results Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for Treatment of B-cell Malignancies caringcross.org ↗
For NHL complete responders, the one-year survival rate was 92.9%, with a median duration of response yet to be reached.
2019-04-01 Fate Therapeutics Results Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting fatetherapeutics.com ↗
FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus

All press releases naming this drug 6 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as CAR19 “Here we develop an anti-CD19 CAR (CAR19) comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.” PMID 34893603 ↗ Dec 2021
1

NCT06911710 ↗
Known as CAR19 T cells “The CAR19 T-cells is used to treat patients with relapsed/refractory pediatric B-cell Acute Lymphocytic Leukemia (ALL; n = 31) or adult B-cell Lymphoma (NHL; n = 23) in two...” PMID 34893603 ↗ Dec 2021
Modality Cell therapy “Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies.” PMID 34893603 ↗ Dec 2021
Route Intravenous “Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.” NCT03467256 ↗
Target CD19 “Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies.” PMID 34893603 ↗ Dec 2021